Osterweis Capital Management Inc. Invests $4.10 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Osterweis Capital Management Inc. bought a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 50,315 shares of the biotechnology company’s stock, valued at approximately $4,101,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Tsfg LLC purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at about $25,000. Optiver Holding B.V. boosted its holdings in shares of Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. Institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Trading Up 2.5%

NASDAQ ARWR opened at $88.88 on Wednesday. The firm has a market cap of $12.52 billion, a PE ratio of -39.50 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $20.59 and a 1-year high of $95.49. The stock has a 50-day moving average of $83.28 and a 200-day moving average of $73.12. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.Arrowhead Pharmaceuticals’s revenue was up 171.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.26) earnings per share. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Royal Bank Of Canada boosted their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Piper Sandler reissued an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Chardan Capital boosted their price objective on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, JPMorgan Chase & Co. increased their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $97.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.